Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

(2021) Frank Dahlke et al.   Multiple Sclerosis Journal

A two‐stage prediction model for heterogeneous effects of treatments

(2021) Konstantina Chalkou et al.   STATISTICS IN MEDICINE

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

(2021) Simone Huygens et al.   VALUE IN HEALTH

The influence of age at disease onset on future relapses and disability progression in multiple sclerosis patients on immunomodulatory treatment

(2020) Viktor von Wyl et al.   EUROPEAN JOURNAL OF NEUROLOGY

Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options

(2020) Marcel F. Jonker et al.   MEDICAL DECISION MAKING

Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies

(2020) Alessio Signori et al.   JAMA Neurology

Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?

(2020) Juan Ignacio Rojas et al.   Multiple Sclerosis and Related Disorders

Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States

(2020) David M. Kern et al.   BMC Neurology

The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

(2020) Per Soelberg Sorensen et al.   BRAIN

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

(2019) Katharine Harding et al.   JAMA Neurology

Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis

(2018) Marita Zimmermann et al.   CNS DRUGS

A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending

(2018) Pieter van Baal et al.   HEALTH ECONOMICS

Unraveling treatment response in multiple sclerosis

(2018) Claudio Gasperini et al.   NEUROLOGY

Indirect comparisons of treatment effects: Network meta-analyses

(2017) Maria Pia Sormani   Multiple Sclerosis Journal

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

(2017) Bernard Uitdehaag et al.   Multiple Sclerosis Journal

Update of the Dutch manual for costing studies in health care

(2017) Tim A. Kanters et al.   PLoS One

Indirect comparisons of treatment effects: Network meta-analyses

(2017) Maria Pia Sormani   Multiple Sclerosis Journal

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

(2017) Bernard Uitdehaag et al.   Multiple Sclerosis Journal

The changing face of multiple sclerosis clinical trial populations

(2011) Bernard M.J. Uitdehaag et al.   CURRENT MEDICAL RESEARCH AND OPINION